Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

HERCEPTIN 400 MG / 250 ML NS IVPB Recalled by Infusion Options, Inc. Due to Lack of Assurance of Sterility

Name: HERCEPTIN 400 MG / 250 ML NS IVPB; HERCEPTIN 340 MG /250 ml 0.9% NACL IVPB; HERCEPTIN 553 MG / 250 ml NS IVPB; HERCEPTIN 305 MG / 250 ml NS IVPB; HERCEPTIN 526 MG / 250 ML NS IVPB; HERCEPTIN 162 MG /
Brand: Infusion Options, Inc.

Date: June 12, 2019

Company: Infusion Options, Inc.

Status: Terminated

Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Infusion Options, Inc. directly.

Affected Products

HERCEPTIN 400 MG / 250 ML NS IVPB; HERCEPTIN 340 MG /250 ml 0.9% NACL IVPB; HERCEPTIN 553 MG / 250 ml NS IVPB; HERCEPTIN 305 MG / 250 ml NS IVPB; HERCEPTIN 526 MG / 250 ML NS IVPB; HERCEPTIN 162 MG / 250 ML NS IVPB; HERCEPTIN 354 MG/ 250 ml 0.9% NACL IVPB; HERCEPTIN 440 MG / 250 ML NS IVPB; HERCEPTIN 650 MG / 250 ML NS IVPB; HERCEPTIN 472 MG / 250 ML NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233

Quantity: N/A

Why Was This Recalled?

Lack of Assurance of Sterility

Where Was This Sold?

This product was distributed to 1 state: NY

About Infusion Options, Inc.

Infusion Options, Inc. has 76 total recalls tracked by RecallDetector.

Related Recalls

Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...

Zydus Pharmaceuticals (USA) Inc · March 9, 2026

Class II — Potential Health Hazard

Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...

Rising Pharma Holding, Inc. · March 3, 2026

Class II — Potential Health Hazard

Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility

New Life Pharma LLC · February 26, 2026

Class II — Potential Health Hazard

Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility

New Life Pharma LLC · February 26, 2026

Class II — Potential Health Hazard

Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility

New Life Pharma LLC · February 26, 2026

Class II — Potential Health Hazard

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report